PE/Cyanine5 anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
145-2C11_PEslashCy5_030206
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE/Cyanine5 (filled histogram) or Armenian hamster IgG PE/Cyanine5 isotype control (open histogram).
  • 145-2C11_PEslashCy5_030206
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE/Cyanine5 (filled histogram) or Armenian hamster IgG PE/Cyanine5 isotype control (open histogram).
Compare all formats See PE/Cyanine5 spectral data
Cat # Size Price Quantity Check Availability
100309 25 µg $77.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100310 100 µg $198.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  2. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  3. Liu W, et al. 2022. Stem Cells Int. 2022:1052166. PubMed
  4. Dölz M, et al. 2022. iScience. 25:105372. PubMed
  5. Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed
  6. Stravokefalou V, et al. 2023. Front Immunol. 13:1014802. PubMed
  7. Tursi NJ, et al. 2023. Front Immunol. 14:1072810. PubMed
  8. van Elsas MJ, et al. 2023. J Immunother Cancer. 11:. PubMed
  9. Saha S, et al. 2023. Sci Rep. 13:4609. PubMed
  10. Rundberg Nilsson A, et al. 2023. iScience. 26:106341. PubMed
  11. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  12. Yang C, et al. 2020. J Control Release. 326:324. PubMed
  13. Liu Y, et al. 2021. Haematologica. Online ahead of print. PubMed
  14. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  15. Mann M, et al. 2018. Cell Rep. 25:2992. PubMed
  16. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
  17. Ciecko AE, et al. 2019. Cell Rep. 29:3073. PubMed
  18. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  19. Salei N, et al. 2020. J Am Soc Nephrol. 31:257. PubMed
  20. Shin JE, et al. 2021. Heliyon. 7:e08433. PubMed
  21. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  22. Li J, et al. 2020. Cancer Discov. . PubMed
  23. Nelson SA, et al. 2022. NPJ Vaccines. 7:124. PubMed
  24. Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed
  25. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  26. Li J, et al. 2018. Immunity. 49:178. PubMed
  27. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  28. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  29. Koma T, et al. 2014. J Virol. 88:7178. PubMed
  30. Balkow S, et al. 2010. Blood. 116:1885. PubMed
  31. Li X, et al. 2009. PLoS One. 4:e6385. PubMed
  32. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
  33. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  34. Nacson J, et al. 2020. Molecular Cell. 78(5):951-959. PubMed
  35. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  36. Naik A, et al. 2015. J Immunol. 194:790. PubMed
  37. Kwok T, et al. 2022. Front Aging. 3:838943. PubMed
  38. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  39. Omatsu Y, et al. 2022. Nat Commun. 13:2654. PubMed
  40. Di Genua C, et al. 2019. Haematologica. 104:2215. PubMed
  41. Koide S, et al. 2022. iScience. 25:103603. PubMed
  42. Riggs JB, et al. 2021. Front Microbiol. 12:656979. PubMed
  43. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  44. Natale CA, et al. 2018. Elife. 7. PubMed
  45. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  46. Halvarsson C, et al. 2019. Antioxid Redox Signal. 31:211. PubMed
  47. Peltzer N, et al. 2018. Nature. 557:112. PubMed
  48. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  49. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
RRID
AB_312674 (BioLegend Cat. No. 100309)
AB_312674 (BioLegend Cat. No. 100310)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login/Register
Forgot your password? Reset Password
Request an Account